BeOne Medicines Q2 FY26 GAAP diluted EPS rises 144% to $2.05 per ADS; revenue climbs 30% to $1.71 billion - ONC News | RalliesBeOne Medicines Q2 FY26 GAAP diluted EPS rises 144% to $2.05 per ADS; revenue climbs 30% to $1.71 billion
O
ONC• Full-year outlook
- Raised FY 2026 revenue outlook to USD 6.6-6.8 billion; GAAP operating income guidance lifted to USD 1-1.1 billion.
Quarterly results
- BeOne Medicines posted Q2 revenue of USD 1.71 billion, up 30% year over year; GAAP diluted EPS per ADS rose to USD 2.05.
- GAAP operating income surged to USD 325.05 million; GAAP net income more than doubled to USD 237.01 million.
- GAAP gross margin expanded 3 percentage points to 90%; free cash flow climbed to USD 435.34 million.
Product revenue performance
- BRUKINSA revenue rose to USD 1.2 billion, up 31%; TEVIMBRA increased to USD 229 million, up 18%.
